The global biopharmaceuticals market accounted for $186,470 million in 2017 and is projected to reach $526,008 million by 2025, registering a CAGR of 13.8% from 2018 to 2025.
Pharmaceutical companies have streamlined drug discovery and development with the adoption of biopharmaceuticals. Biopharmaceuticals and therapeutic proteins have been very useful for target-based treatment of chronic diseases, especially cancer.
Biopharmaceuticals are substances that are produced using living organisms, such as microorganisms and animal cells, and have a high-therapeutic value. These large and complex molecular drugs are also known as biologics and biotech drugs.
The global biopharmaceuticals market is driven by various factors, such as increase in elderly population, surge in prevalence of chronic diseases such as cancer and diabetes, and increase in adoption of biopharmaceuticals globally. Furthermore, rise in strategic collaborations among biopharmaceuticals companies is also anticipated to supplement the growth of the biopharmaceuticals industry.
Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/3971
The Biopharmaceuticals Market report provides an extensive competitive analysis and profiles of the key market players, such as Abbott Laboratories, Amgen, Inc., Biogen, Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Ltd., Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Pfizer, Inc., and Sanofi. The other players in the value chain (not included in the report) include Bristol Myers Squibb Company, Bayer AG, and Shire plc.
Biopharmaceuticals, also known as biologics, are drugs that are manufactured in living systems, such as microorganisms and animal cells. An array of different biopharmaceuticals is also produced using recombinant DNA technology. The biopharmaceuticals sector is the fastest-growing segment of the pharmaceutical industry.
The global biopharmaceuticals market is anticipated to grow considerably in the near future, owing to various factors, such as strategic collaborations among biopharmaceuticals companies, increase in obesity and sedentary lifestyle among the population, rise in elderly population, and upsurge in prevalence of chronic diseases, such as cancer, globally. However, high costs associated with biopharmaceuticals drug development and a stringent regulatory scenario are key factors expected to impede the market growth. On the contrary, emerging markets, such as India and China, are anticipated to provide lucrative growth opportunities to the market players during the forecast period.
By type, the monoclonal antibody segment accounted for nearly two-fifths share of the global biopharmaceuticals market in 2017. In terms of application, the oncology segment accounted for one-third share in 2017, and is projected to exhibit a prominent growth rate, owing to surge in cancer prevalence globally. By region, North America generated the highest revenue in the global biopharmaceuticals market in 2017.
Key Findings of the Biopharmaceuticals Market:
- The monoclonal antibody segment is anticipated to dominate the global biopharmaceuticals market from 2018 to 2025.
- The metabolic disease application is anticipated to grow with the highest CAGR throughout the forecast period.
- North America accounted for a share of more than two-fifths of the global biopharmaceuticals market in 2017.
- The Asia-Pacific region is anticipated to grow at the highest rate in the global biopharmaceuticals market during the forecast period, followed by LAMEA.
For More Information @ https://www.alliedmarketresearch.com/request-for-customization/3971
North America held the highest market share in 2017, owing to high prevalence rate of cancer and other chronic diseases, adoption of biologics, and increase in awareness about biopharmaceuticals. The Asia-Pacific region is expected to grow at the highest CAGR of 17.2% during the forecast period, owing to rapid industrialization in the area, increase in disposable income, and upsurge in government initiatives to modernize the healthcare infrastructure.
Rise in focus of vendors on the emerging markets, such as Asia-Pacific and LAMEA, is expected to boost the market growth. The Asia-Pacific region is projected to witness significant growth in future, owing to increase in R&D investment, rise in adoption and availability of biopharmaceuticals for disease treatment and surge in disease diagnosis awareness. Furthermore, this region presents remarkable opportunities for venture capitalists and investors, because the developed markets are comparatively saturated.
Access Full Summery @ https://www.alliedmarketresearch.com/biopharmaceutical-market
About us
Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.
Contact
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com